MOSCOW (MRC) -- Arkema has successfully brought on stream a new production line for ultra-high performance polyamide 12 powders at the Mont plant in France, according to the company's press release.
The Group thus increases its global capacity by over 50% to support the increase in demand for fast-growing niche industrial applications, in particular in the coatings, personal care, composites and 3D printing markets.
This investment of some EUR20 million in specialty polyamide powders at Mont in France will contribute to the Group’s strategy to accelerate its development in advanced materials.
Arkema’s specialty polyamide 12 powders are marketed under the brand name Orgasol.
They are known for their exceptionally narrow particle size distribution and their outstanding toughness.
They are often used in high performance formulations for the coatings and personal care markets, as well as in advanced composite materials for the aerospace market.
Thanks to their stability and recyclability, they are also extensively used in the fast-growing 3D printing market.
"The Mont site has a long, proven legacy in the production of specialty powders. With this new production capacity, we continue to actively support our customers’ continued growth in cutting edge applications, notably in high performance coatings, composites and 3D printing," - said Erwoan Pezron, Global President, Technical Polymers Business Line.
As MRC reported before, in late January 2017, Arkema announced a project for the sale to INEOS of its 50% stake in Oxochimie. Arkema produced oxo alcohols on the Lavera site (France) in a 50/50 manufacturing joint venture with INEOS. These products were used in part for the production of the group’s acrylic esters in Europe. And in early March 2017, Arkema completed the sale to INEOS of its 50% stake in Oxochimie, their oxo alcohols manufacturing joint venture, and of the associated business.
Arkema is a leading European supplier of chlorochemicals and PVC. Kynar and Kynar Flex are registered trademarks of Arkema Inc.
MRC